Rigel Pharmaceuticals has granted 35,275 restricted stock units to 18 non-executive employees under its inducement plan. The biotechnology company made the awards on October 2, 2026, following approval by the compensation committee of Rigel’s board of directors.
Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
The equity awards were issued in accordance with NASDAQ Listing Rule 5635(c)(4), which allows for inducement grants as a material condition of entering into employment. The newly issued restricted stock units vest over a four-year period. Twenty-five percent of each grant vests annually until fully vested.
Rigel Develops Therapies for Cancer and Hematologic Disorders
Founded in 1996, Rigel is headquartered in South San Francisco, California. The publicly traded biotechnology firm operates under the ticker symbol RIGL on the Nasdaq exchange. The company focuses on discovering, developing, and commercializing therapies intended for patients with hematologic disorders and cancer. Additional information regarding the company’s marketed products and clinical pipeline is available through the official Rigel website.
What Are the Details of Rigel Stock Units?
-
What is the total number of restricted stock units granted by Rigel?
Rigel granted a total of 35,275 restricted stock units under the inducement plan announced on October 2, 2026. -
How many employees received the equity awards?
Eighteen non-executive employees received the restricted stock units as an inducement material to entering into employment with the company. -
What is the vesting schedule for the grants?
The restricted stock units vest over a four-year period, with 25 percent of the grant vesting each year. -
Under which regulatory rule were the awards issued?
The awards were granted pursuant to NASDAQ Listing Rule 5635(c)(4) following approval by the compensation committee of Rigel’s board of directors.
Worth a look